• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

High-pressure liquid chromatographic assay for hydralazine in human plasma.

作者信息

Ludden T M, Goggin L K, McNay J L, Haegele K D, Shepherd A M

出版信息

J Pharm Sci. 1979 Nov;68(11):1423-5. doi: 10.1002/jps.2600681123.

DOI:10.1002/jps.2600681123
PMID:512893
Abstract

A specific high-performance liquid chromatographic assay for hydralazine in human plasma was developed. Plasma hydralazine is reacted with 10 microliter of p-anisaldehyde for 7 min at room temperature to form hydralazine p-anisaldehyde hydrazone. This derivative is extracted into ethyl acetate, and the solvent is removed by evaporation. The residue is reconstituted in 100 microliter of methanol, and 90 microliter is injected onto a reversed-phase column. The mobile phase is 32% acetonitrile in 0.75 M acetate buffer, pH 3.4, at a flow rate of 2 ml/min. The retention time of hydralazine p-anisaldehyde hydrazone is 6.5 min. The average coefficient of variation over 10-200 ng/ml is 5.5%, and the sensitivity limit is 5 ng/ml. Under the assay conditions, hydralazine pyruvic acid hydrazone, a known plasma metabolite of hydralazine, yields less than 0.1% hydralazine. Detectable plasma hydralazine levels of 5-20 ng/ml were found 10-30 min after a 0.5-mg/kg oral dose of hydralazine hydrochloride was given to a male volunteer.

摘要

相似文献

1
High-pressure liquid chromatographic assay for hydralazine in human plasma.
J Pharm Sci. 1979 Nov;68(11):1423-5. doi: 10.1002/jps.2600681123.
2
Determination of hydralazine in human whole blood.
J Pharm Sci. 1983 Jun;72(6):693-5. doi: 10.1002/jps.2600720624.
3
Selective high-performance liquid chromatographic assays for hydralazine and its metabolites in plasma of man.
J Chromatogr. 1980 Mar 14;181(3-4):427-40. doi: 10.1016/s0378-4347(00)81145-7.
4
Quantitative analysis of hydralazine pyruvic acid hydrazone, the major plasma metabolite of hydralazine.
J Chromatogr. 1980 Jan 4;187(1):171-9. doi: 10.1016/s0021-9673(00)87883-8.
5
Determination of hydralazine in human plasma by high-performance liquid chromatography with electrochemical detection.
J Chromatogr. 1987 Jan 9;385:261-6. doi: 10.1016/s0021-9673(01)94638-2.
6
Assay for hydralazine as its stable p-nitrobenzaldehyde hydrazone.以其稳定的对硝基苯甲醛腙形式测定肼屈嗪。
Pharm Res. 1988 Jun;5(6):383-6. doi: 10.1023/a:1015915812987.
7
Liquid chromatographic determination of hydralazine in human plasma with 2-hydroxy-1-naphthaldehyde pre-column derivatization.
J Pharm Biomed Anal. 1990;8(8-12):795-8. doi: 10.1016/0731-7085(90)80123-7.
8
Interference in assays for hydralazine in humans by a major plasma metabolite, hydralazine pyruvic acid hydrazone.
J Pharm Sci. 1978 Aug;67(8):1150-3. doi: 10.1002/jps.2600670833.
9
Pharmacokinetics of hydralazine, apparent hydralazine and hydralazine pyruvic acid hydrazone in humans.
Res Commun Chem Pathol Pharmacol. 1979 Oct;26(1):129-44.
10
Stability problems with hydralazine p-anisaldehyde hydrazone.
J Pharm Sci. 1989 May;78(5):432-4. doi: 10.1002/jps.2600780518.

引用本文的文献

1
Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy.乙酰转移酶 2 基因型对妊娠期肼屈嗪药代动力学的影响。
J Clin Pharmacol. 2019 Dec;59(12):1678-1689. doi: 10.1002/jcph.1477. Epub 2019 Jun 30.
2
Clinical pharmacokinetics of hydralazine.肼屈嗪的临床药代动力学。
Clin Pharmacokinet. 1982 May-Jun;7(3):185-205. doi: 10.2165/00003088-198207030-00001.
3
Assay for hydralazine as its stable p-nitrobenzaldehyde hydrazone.以其稳定的对硝基苯甲醛腙形式测定肼屈嗪。
Pharm Res. 1988 Jun;5(6):383-6. doi: 10.1023/a:1015915812987.
4
Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure.肼屈嗪在充血性心力衰竭中的临床药代动力学及治疗应用
Clin Pharmacokinet. 1989 Feb;16(2):86-9. doi: 10.2165/00003088-198916020-00003.